 |
|
Stroke Complicating Acute Myocardial InfarctionA Meta-analysis of Risk Modification by Anticoagulation and Thrombolytic Therapy
Paul T. Vaitkus, MD;
Jesse A. Berlin, ScD;
J. Sanford Schwartz, MD;
Elliot S. Barnathan, MD
Arch Intern Med. 1992;152(10):2020-2024.
Abstract
| |
Background.—
The objective of this meta-analysis was to examine the impact of systemic anticoagulation and thrombolysis on the total incidence of stroke following myocardial infarction. Additionally, we sought to compare the relative risk of stroke with different thrombolytic agents.
Methods.—
A computerized and manual literature search for controlled clinical trials of anticoagulants and thrombolytic agents in myocardial infarction reporting on total strokes in treated and control patients was used. Pooling was performed by calculating the Mantel-Haenszel odds ratio and 95% confidence interval (CI).
Results.—
The Mantel-Haenszel pooled odds ratio for anticoagulation trials was 0.46 (95% CI, 0.30 to 0.64), suggesting a benefit of anticoagulant therapy. However, a statistically significant degree of variability (heterogeneity) was present among study results. The odds ratios for all thrombolytic trials, tissue plasminogen activator, and streptokinase trials, respectively, were 1.08 (95% CI, 0.87 to 1.35), 1.28 (95% CI, 0.76 to 2.17), and 1.02 (95% CI, 0.80 to 1.30), suggesting no overall excess of stroke with thrombolysis. The pooled odds ratio for three studies directly comparing streptokinase and tissue plasminogen activator was 0.73 (95% CI, 0.61 to 0.86), suggesting an excess of stroke for patients treated with tissue plasminogen activator in comparison with streptokinase-treated patients.
Conclusions.—
The available data may support a role for anticoagulants in reducing the incidence of stroke after myocardial infarction, but the heterogeneity among the trials makes interpretation of this effect difficult. Although the available data do not indicate an increase in stroke with thrombolysis, a direct comparison of tissue plasminogen activator and streptokinase reveals an excess of strokes with tissue plasminogen activator.
(Arch Intern Med. 1992;152:2020-2024)
Author Affiliations
From the Cardiovascular and General Internal Medicine Sections and Clinical Epidemiology Unit, Department of Medicine, School of Medicine, University of Pennsylvania (Drs Vaitkus, Berlin, and Barnathan), and the Health Care Systems Department, Wharton School of Business, and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (Dr Schwartz). Dr Vaitkus is presently with the Cardiology Unit, Medical Center Hospital of Vermont, Burlington.
Footnotes
Accepted for publication March 20, 1992.
Reprint requests to Cardiology Unit, Medical Center Hospital of Vermont, Burlington, VT 05401 (Dr Vaitkus).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke With Acute Myocardial Infarction
Van De Graaff et al.
Stroke 2006;37:2546-2551.
ABSTRACT
| FULL TEXT
A Community-Based Study of Stroke Incidence after Myocardial Infarction
Witt et al.
ANN INTERN MED 2005;143:785-792.
ABSTRACT
| FULL TEXT
Improvements in Treatment of Coronary Heart Disease and Cessation of Stroke Mortality Rate Decline
Peeters et al.
Stroke 2003;34:1610-1614.
ABSTRACT
| FULL TEXT
Evidence based cardiology: Prevention of ischaemic stroke
Barnett et al.
BMJ 1999;318:1539-1543.
FULL TEXT
Thrombolysis-Related Intracranial Hemorrhage : A Radiographic Analysis of 244 Cases From the GUSTO-1 Trial With Clinical Correlation
Gebel et al.
Stroke 1998;29:563-569.
ABSTRACT
| FULL TEXT
Ischemic Stroke After Acute Myocardial Infarction : A Population-Based Study
Mooe et al.
Stroke 1997;28:762-767.
ABSTRACT
| FULL TEXT
Drugs and Surgery in the Prevention of Ischemic Stroke
Barnett et al.
NEJM 1995;332:238-248.
FULL TEXT
|
